未找到相关数据
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2-advanced breast cancer
被引：0
作者：
Wu, Jiong
Zhang, Jian
Li, Man
Cai, Li
Sun, Tao
Ouyang, Quchang
Meng, Yanchun
Shi, Yehui
Wang, Chuan
Liu, Qiang
Lu, Yongkui
Yin, Yongmei
Chen, Qianjun
Chen, Lilin
Wang, Haitao
Cui, Jiuwei
Liao, Ning
Wang, Shubin
Tu, Yi
Yan, Min
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Second Hosp Dalian Med Univ, Dalian, Peoples R China
[3] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[4] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[5] Hunan Canc Hosp, Changsha, Peoples R China
[6] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[7] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[8] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[9] Guangxi Med Univ, Canc Ctr, Nanning, Guangxi, Peoples R China
[10] Jiangsu Prov Hosp, Nanjing, Peoples R China
[11] Chinese Med Breast Ctr, Guangdong Prov Hosp, Guangzhou, Peoples R China
[12] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[13] Second Hosp Tianjin Med Univ, Tianjin, Peoples R China
[14] First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China
[15] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[16] Peking Univ Shenzhen Hosp, Shenzhen, Peoples R China
[17] Wuhan Univ, RenMin Hosp, Wuhan, Peoples R China
[18] Henan Canc Hosp, Zhengzhou, Peoples R China
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1047
引用
收藏
页数：1
相关论文